Organon & (OGN)

Search documents
Organon & Co. Investors: Please contact the Portnoy Law Firm to recover your losses; July 22, 2025 Deadline to file Lead Plaintiff Motion
GlobeNewswire News Room· 2025-07-18 20:46
Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy and dividend policies during the specified Class Period [1][3]. Group 1: Class Action Details - The class action represents investors who purchased Organon securities between November 3, 2022, and April 30, 2025 [1]. - Investors have until July 22, 2025, to file a lead plaintiff motion [1]. Group 2: Allegations Against Organon - The lawsuit claims that Organon concealed critical information about its capital allocation strategy, particularly regarding its quarterly dividend payout [3]. - Despite public statements indicating that maintaining the dividend was a top priority, Organon had adopted a debt reduction strategy that conflicted with this commitment [3]. - Following the acquisition of Dermavant Sciences Ltd., Organon intended to prioritize debt reduction, which led to a significant cut in its dividend [3]. Group 3: Financial Impact - On May 1, 2025, Organon announced a drastic reduction in its quarterly dividend from $0.28 to $0.02 per share [4]. - This announcement resulted in a stock decline of more than 27% [4].
OGN SECURITIES FRAUD: Organon & Co. (NYSE:OGN) 27% Stock Drop Triggers Class Action Lawsuit – Contact BFA Law by July 22 Legal Deadline
GlobeNewswire News Room· 2025-07-18 13:07
Core Viewpoint - A lawsuit has been filed against Organon & Co. and its senior executives for potential violations of federal securities laws, particularly related to misleading statements about dividend policies following a significant acquisition [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction [3]. - On May 1, 2025, Organon announced a drastic cut in its dividend payout from $0.28 per share to $0.02 per share, leading to a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].
Shareholders that lost money on Organon & Co.(OGN) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More
GlobeNewswire News Room· 2025-07-17 20:14
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Organon & Co. ("Organon" or the "Company") (NYSE: OGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Organon investors who were adversely affected by alleged securities fraud between October 31, 2024 and April 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/organon-co-lawsuit-submission-for ...
The Gross Law Firm Reminds Organon & Co. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 22, 2025 - OGN
Prnewswire· 2025-07-17 13:00
NEW YORK, July 17, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Organon & Co. (NYSE: OGN).Shareholders who purchased shares of OGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/organon-co-loss-submission-form/?id=156851&from=4CLASS PERIOD: October 31, 2024 to April 30, 20 ...
OGN DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Organon & Co. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 22 Deadline in Securities Class Action – OGN
GlobeNewswire News Room· 2025-07-16 20:01
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between November 3, 2022 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...
INVESTOR DEADLINE NEXT WEEK: Robbins Geller Rudman & Dowd LLP Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – OGN
GlobeNewswire News Room· 2025-07-16 15:15
SAN DIEGO, July 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that it has filed a class action lawsuit seeking to represent purchasers of Organon & Co. (NYSE: OGN) publicly traded securities between November 3, 2022 and April 30, 2025, both dates inclusive (the “Class Period”). Captioned Lerner v. Organon & Co., No. 25-cv-12983 (D.N.J.), the Organon class action lawsuit charges Organon as well as certain of Organon’s top executives with violations of the Securities ...
Organon & Co. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before July 22, 2025 to Discuss Your Rights – OGN
GlobeNewswire News Room· 2025-07-16 13:13
Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Organon & Co. regarding a class action lawsuit due to alleged misleading statements and concealment of material facts related to the company's capital allocation and dividend strategy [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that Organon & Co. provided overly positive statements to investors while concealing significant adverse facts about its priorities, particularly regarding capital allocation and a debt reduction strategy following the acquisition of Dermavant [3]. - The company reportedly reduced its regular quarterly dividend by 70%, which was not disclosed to investors prior to the announcement [3]. Stock Price Impact - Following the announcement of the dividend cut, Organon's stock price fell from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [3]. Class Action Details - The class period for the lawsuit is defined as October 31, 2024, to April 30, 2025, and shareholders are encouraged to register for participation in the class action [3][4]. - The deadline for shareholders to seek lead plaintiff status is July 22, 2025, and there is no cost or obligation to participate in the case [4]. Firm's Commitment - The Gross Law Firm emphasizes its mission to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements [5].
OGN INVESTOR LOSS: A Class Action was filed on behalf of Organon & Co. (NYSE:OGN) Investors – Contact BFA Law by July 22 if you Suffered Losses
GlobeNewswire News Room· 2025-07-16 12:18
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action. Investors have until July 22, 2025, to ask the Court to be appointed to lea ...
ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Organon & Co. - OGN
GlobeNewswire News Room· 2025-07-16 02:19
Core Viewpoint - Investors have until July 22, 2025, to file lead plaintiff applications in securities class action lawsuits against Organon & Co. for failing to disclose material information during the class period from November 3, 2022, to April 30, 2025 [1][3] Company Information - Organon & Co. is facing lawsuits for allegedly violating federal securities laws by not disclosing important information during the specified class period [3] - The company announced a significant reduction in its dividend payout from $0.28 to $0.02 on March 10, 2025, which contradicted previous assurances to investors about maintaining the dividend [4] Financial Impact - Following the announcement of the dividend cut, Organon's share price dropped over 27%, from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025 [4] Legal Proceedings - The first filed case is Hauser v. Organon & Co., et al., No. 25-cv-05322, with a subsequent case, Lerner v. Organon & Co., et al., No. 25-cv-12983, expanding the class period [5]
ORGANON DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Organon & Co. (OGN) to Inquire About Their Rights in Class Action Lawsuit
GlobeNewswire News Room· 2025-07-15 23:04
Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly providing misleading statements to investors while concealing material adverse facts regarding the company's capital allocation priorities, particularly concerning its dividend policy [2][4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased Organon securities between November 3, 2022, and April 30, 2025, with a deadline of July 22, 2025, for investors to apply as lead plaintiffs [2]. - The complaint alleges that the defendants made overwhelmingly positive statements while concealing the high priority of debt reduction following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. Group 2: Stock Price Impact - Following the announcement of the lawsuit and the revelations regarding the dividend cut, Organon's stock price plummeted from $12.93 per share on April 30, 2025, to $9.45 per share on May 1, 2025, marking a decline of over 27% in just one day [5]. Group 3: Investor Outreach - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact the law firm Bragar Eagel & Squire, P.C. for more information [6].